Trial · NCT05672316
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recommended phase 2 dose of botensilimab, balstilimab, and regorafenib (Phase I) | Cycle 1 (6 weeks) | Will conduct a Simon 2-stage optimal design study. |
| Primary | Incidence of dose limiting toxicities (DLT) (Phase I) | Cycle 1 (6 weeks) | Graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0. |
| Primary | Overall response rate (ORR) (Phase II) | Up to 2 years | Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. |
| Secondary | Incidence of DLTs (Phase I) | Up to 2 years | Graded according to the NCI CTCAE v.5.0. |
| Secondary | ORR (Phase I) | Up to 2 years | Assessed by RECIST 1.1. |
| Secondary | Progression-free survival (PFS) (Phase I) | Time to disease progression/ relapse or death as a result of any cause, assessed up to 2 years | |
| Secondary | Overall survival (OS) (Phase I) | Time to death as a result of any cause, assessed up to 2 years | |
| Secondary | PFS (Phase II) | Time to disease progression or death as a result of any cause, assessed up to 2 years | |
| Secondary | OS (Phase II) | Time to death as a result of any cause, assessed up to 2 years | |
| Secondary | Duration of response (Phase II) | Time to progression or death, starting at the time when a response is experienced, assessed up to 2 years | |
| Secondary | Incidence of toxicity (Phase II) | Up to 2 years | Graded according to the NCI CTCAE v.5.0. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05672316/registered